Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS
Krishan K PandeyInstitute for Molecular Virology, Saint Louis University Health Sciences Center, St Louis, MO, USAAbstract: Human immunodeficiency virus type 1 (HIV-1) integrase inhibitors belong to a novel class of antiretroviral drugs with high potency and better tolerability. Elvitegravir (EVG) i...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-05-01
|
| Series: | HIV/AIDS: Research and Palliative Care |
| Online Access: | http://www.dovepress.com/critical-appraisal-of-elvitegravir-in-the-treatment-of-hiv-1aids-a16863 |
| _version_ | 1818461107535216640 |
|---|---|
| author | Pandey KK |
| author_facet | Pandey KK |
| author_sort | Pandey KK |
| collection | DOAJ |
| description | Krishan K PandeyInstitute for Molecular Virology, Saint Louis University Health Sciences Center, St Louis, MO, USAAbstract: Human immunodeficiency virus type 1 (HIV-1) integrase inhibitors belong to a novel class of antiretroviral drugs with high potency and better tolerability. Elvitegravir (EVG) is the second integrase inhibitor approved by the US Food and Drug Administration when administered in combination with a novel pharmacoenhancer, cobicistat (COBI), and two nucleoside/nucleotide reverse transcriptase inhibitors, emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF). This combination of drugs (EVG/COBI/FTC/TDF) developed and marketed by Gilead Sciences Inc. (Foster City, CA, USA) as STRIBILD®, is the first integrase inhibitor-based single-tablet regimen administered once-daily. In the USA, it has been approved for use in antiretroviral treatment-naïve HIV-1 patients with estimated creatinine clearance of >70 mL/min. The Department of Health and Human Services has approved EVG/COBI/FTC/TDF as one of preferred first-line regimens for HIV-1 treatment. In Europe, the European Medicines Agency has approved STRIBILD in treatment-naïve patients as well as in patients having no resistant mutation to any of the antiviral agents contained in STRIBILD. Its availability as a fixed-dose combination and once-daily dosage makes the adherence highly likely. However, it also discounts the possibility of dosage adjustment if needed.Keywords: STRIBILD, INSTI, integrase, EVG/COBI/FTC/TDF |
| first_indexed | 2024-12-14T23:40:53Z |
| format | Article |
| id | doaj.art-c93ccd2a03dd4d348281ebbadd87a718 |
| institution | Directory Open Access Journal |
| issn | 1179-1373 |
| language | English |
| last_indexed | 2024-12-14T23:40:53Z |
| publishDate | 2014-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | HIV/AIDS: Research and Palliative Care |
| spelling | doaj.art-c93ccd2a03dd4d348281ebbadd87a7182022-12-21T22:43:31ZengDove Medical PressHIV/AIDS: Research and Palliative Care1179-13732014-05-012014default819016863Critical appraisal of elvitegravir in the treatment of HIV-1/AIDSPandey KKKrishan K PandeyInstitute for Molecular Virology, Saint Louis University Health Sciences Center, St Louis, MO, USAAbstract: Human immunodeficiency virus type 1 (HIV-1) integrase inhibitors belong to a novel class of antiretroviral drugs with high potency and better tolerability. Elvitegravir (EVG) is the second integrase inhibitor approved by the US Food and Drug Administration when administered in combination with a novel pharmacoenhancer, cobicistat (COBI), and two nucleoside/nucleotide reverse transcriptase inhibitors, emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF). This combination of drugs (EVG/COBI/FTC/TDF) developed and marketed by Gilead Sciences Inc. (Foster City, CA, USA) as STRIBILD®, is the first integrase inhibitor-based single-tablet regimen administered once-daily. In the USA, it has been approved for use in antiretroviral treatment-naïve HIV-1 patients with estimated creatinine clearance of >70 mL/min. The Department of Health and Human Services has approved EVG/COBI/FTC/TDF as one of preferred first-line regimens for HIV-1 treatment. In Europe, the European Medicines Agency has approved STRIBILD in treatment-naïve patients as well as in patients having no resistant mutation to any of the antiviral agents contained in STRIBILD. Its availability as a fixed-dose combination and once-daily dosage makes the adherence highly likely. However, it also discounts the possibility of dosage adjustment if needed.Keywords: STRIBILD, INSTI, integrase, EVG/COBI/FTC/TDFhttp://www.dovepress.com/critical-appraisal-of-elvitegravir-in-the-treatment-of-hiv-1aids-a16863 |
| spellingShingle | Pandey KK Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS HIV/AIDS: Research and Palliative Care |
| title | Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS |
| title_full | Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS |
| title_fullStr | Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS |
| title_full_unstemmed | Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS |
| title_short | Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS |
| title_sort | critical appraisal of elvitegravir in the treatment of hiv 1 aids |
| url | http://www.dovepress.com/critical-appraisal-of-elvitegravir-in-the-treatment-of-hiv-1aids-a16863 |
| work_keys_str_mv | AT pandeykk criticalappraisalofelvitegravirinthetreatmentofhiv1aids |